Clinical Trials Browser

Phase 1/2 × regorafenib × Other solid neoplasm × Clear all

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Phase 1/2 Not yet recruiting

380 enrolled

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

747 enrolled

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT04200404 2022-05-06

A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors

Phase 1/2 Completed

19 enrolled

Other solid neoplasm

Advanced Refractory Solid Tumors